Skip to content

迷宫制药

US · MAZE #2998 按市值排名 上市于 2025
27.53 +0.05 +0.18%
实时 - 追踪5344个代码 - 心跳于394秒前 · 2026-10-16 20:02

✦ 量化股权信号 计算方式说明

减持
  • 最近一期（2026/Q3）披露持股的机构数量减少了1家。
  • 机构持股总比例下降了2.8个百分点。

机构持股

机构持股比例
106.30% -2.85pp
机构数量
197 -1
数据截至
2026/Q3 较上一报告期

持股变动 vs 资金流向

方向分歧

机构在上一报告期减持了股份，同时该股在最近20个交易日的主力资金呈净流入——两者方向出现分歧。

机构持股变动数据按季度发布且存在滞后；资金流向数据为每日更新。请将其作为方向性的交叉验证参考，而非精确的择时信号。

持股人类型

VC/PE Fund46.44%
Mutual Fund38.55%
Hedge Fund19.02%
Public Company1.70%
Individual/Insider0.80%
Private Company0.40%
Government Pension Fund0.16%

主要股东 截至 2026-06-30

Third Rock Ventures, LLC 9.77% · 5.42M 股
Frazier Life Sciences Management, LP 9.06% · 5.03M 股
Arch Venture Partners, L.P. 7.42% · 4.12M 股
Deep Track Capital, LP 6.72% · 3.73M 股
BlackRock 6.31% · 3.50M 股
Janus Henderson Group plc 6.14% · 3.41M 股
T. Rowe Price Group, Inc. 4.93% · 2.74M 股
Vanguard Capital Management, LLC 3.60% · 2.00M 股
Logos Global Management, L.P. 3.48% · 1.94M 股
Andreessen Horowitz LLC 3.06% · 1.70M 股

条形长度是相对于此处列出的最大股东而言，并非相对于公司100%股权。

内部人持股

共追踪50份申报 · 17次买入 · 33次卖出

姓名职务持股比例
Jason Coloma Chief Executive Officer 0.42%
Sekar Kathiresan Independent Director 0.19%
Atul Dandekar Chief Strategy & Business Officer 0.06%
Charles Homcy Chairperson 0.06%
Jonathan Lim Independent Director 0.04%
Amy Bachrodt Chief Financial Officer 0.02%
Courtney Phillips General Counsel 0.01%
Daniel Spiegelman Independent Director --
Richard Scheller Independent Director --
Paula Johnson Director --

内部人交易 最近的 Form 4 申报记录

日期姓名职务类型股数价格
2026-09-30 Jason Coloma Chief Executive Officer Automatic Disposition -34,501 $27.02–27.02
2026-09-30 Harold Bernstein President, Head of Research & Development and Chief Medical Officer Derivative Exercise and Sale -16,141 $10.42–26.93
2026-09-28 Atul Dandekar Chief Strategy & Business Officer Derivative Exercise and Sale -7,500 $10.42–27.06
2026-09-03 Harold Bernstein President, Head of Research & Development and Chief Medical Officer Automatic Disposition -9,705 $26.22
2026-09-02 Jason Coloma Chief Executive Officer Open Market Disposition -22,638 $25.77–27.12
2026-09-02 Atul Dandekar Chief Strategy & Business Officer Open Market Disposition -6,434 $25.81–27.12
2026-09-02 Courtney Phillips General Counsel Open Market Disposition -3,993 $25.78–27.12
2026-09-02 Harold Bernstein President, Head of Research & Development and Chief Medical Officer Open Market Disposition -10,295 $25.78–27.12
2026-09-01 Courtney Phillips General Counsel Intent to Sell (Form 144) -4,144 $26.54
2026-09-01 Harold Bernstein President, Head of Research & Development and Chief Medical Officer Intent to Sell (Form 144) -10,685 $26.53
2026-08-31 Jason Coloma Chief Executive Officer Automatic Disposition -34,501 $26.29–26.31
2026-08-31 Jason Coloma Chief Executive Officer Derivative Exercise and Retained +50,000 --
2026-08-31 Atul Dandekar Chief Strategy & Business Officer Derivative Exercise and Retained +12,500 --
2026-08-31 Courtney Phillips General Counsel Derivative Exercise and Retained +11,000 --
2026-08-31 Harold Bernstein President, Head of Research & Development and Chief Medical Officer Derivative Exercise and Sale -16,141 $10.42–26.36
2026-08-31 Harold Bernstein President, Head of Research & Development and Chief Medical Officer Derivative Exercise and Retained +20,000 --
2026-08-27 Atul Dandekar Chief Strategy & Business Officer Derivative Exercise and Sale -7,500 $10.42–27.58
2026-08-12 Paula Johnson Director Other Derivative Acquisition +36,000 $27.67
2026-08-12 Harold Bernstein President, Head of Research & Development and Chief Medical Officer Derivative Exercise and Sale -16,142 $10.42–27.61
2026-08-02 Jason Coloma Chief Executive Officer Automatic Disposition -34,501 $26.71–27.09

Form 4 申报记录，每家公司显示最新的一批。"Other Derivative Acquisition"（其他衍生品获取）类目多为限制性股票/期权归属，并非公开市场买入——具体类型见"类型"列。

报价时间 2026-10-16 20:02:21 · 仅供参考，不构成投资建议，也未考虑您的具体情况。

迷宫制药 讨论区 0 条评论

发表评论